Statement: all the primary trial patients achieved either disappearance of all target lesions, <=10% increase in the sum of the longest diameter of target lesions or a tumor that is neither growing nor shrinking.
Primary_evidence: Outcome Measurement:    Complete Response + Partial Response + Stable Disease > 24 Weeks   Clinical Outcome measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), a tumor that is neither growing nor shrinking.   A patient has clinical benefit from treatment if CR + PR + SD > 24 weeks.   Time frame: 24 weeks Results 1:    Arm/Group Title: Sorafenib and Anastrozole   Arm/Group Description: All patients receive sorafenib and anastrozole.   Overall Number of Participants Analyzed: 35   Measure Type: Number   Unit of Measure: participants  35